Ticagrelor versus Clopidogrel in <i>CYP2C19</i> Loss-of-Function Carriers with Stroke or TIA

Wang, Yongjun; Meng, Xia; Wang, Anxin; Xie, Xuewei; Pan, Yuesong; Claiborne Johnston, S.; Li, Hao; M. Bath, Philip; Dong, Qiang; Xu, Anding; Jing, Jing; Lin, Jinxi; Niu, Siying; Wang, Yilong; Zhao, Xingquan; Li, Zixiao; Jiang, Yong; Li, Wei; Liu, Liping; Xu, Jie; Chang, Liguo; Wang, Lihua; Zhuang, Xianbo; Zhao, Jinguo; Feng, Yefang; Man, Honghao; Li, Guozhong; Wang, Baojun

doi:10.1056/nejmoa2111749

Public

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA

Published in New England Journal of Medicine • Oct 28, 2021

Authors:

Yongjun Wang

Xia Meng

Anxin Wang

Abstract

BACKGROUND: loss-of-function carriers have not been extensively performed. METHODS: loss-of-function alleles. Patients were assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2 through 90) and placebo clopidogrel...

Subject

Ticagrelor

Clopidogrel

CYP2C19

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!